Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Company Overview

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and manufacturing of vaccines and injectable therapeutics. Headquartered in Fort Lauderdale, Florida, the company leverages proprietary formulation and drug‐delivery platforms to enhance the stability, bioavailability and tolerability of its product candidates. Virpax’s integrated model spans early-stage discovery through cGMP manufacturing, enabling seamless progression from laboratory proof‐of‐concept to large-scale production.

Virpax’s pipeline encompasses a range of vaccine candidates targeting diseases such as rabies, herpes zoster and other infectious threats. Its proprietary adjuvant systems and lipid-based delivery technologies are designed to optimize immune responses while minimizing reactogenicity. In addition to vaccines, the company develops specialty injectable formulations for small molecules and biologics, addressing challenges related to solubility, absorption and patient compliance. Virpax advances its programs through collaborations with academic institutions, government agencies and contract development organizations, reinforcing its focus on both endemic and emerging health risks.

Since its founding, Virpax has invested in scalable U.S. manufacturing capabilities that adhere to current Good Manufacturing Practices. The company’s strategic emphasis on vaccine innovation and formulation expertise positions it to serve domestic and selected international markets. As Virpax progresses its pipeline through preclinical and clinical milestones, its leadership continues to pursue partnerships and licensing opportunities to accelerate the development and commercialization of its vaccine and injectable portfolios.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.01 to $0.33
• 52-Week Range: $0.01 to $26.25
• Volume: 18 shs
• Average Volume: 156,335 shs
• Market Capitalization: $31.17 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Virpax Pharmaceuticals Stock Analysis - MarketRank™

Virpax Pharmaceuticals scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Virpax Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Virpax Pharmaceuticals has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virpax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Virpax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Virpax Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Virpax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed this year?

Virpax Pharmaceuticals' stock was trading at $9.4975 at the beginning of 2025. Since then, VRPX shares have decreased by 99.7% and is now trading at $0.0251.

When did Virpax Pharmaceuticals' stock split?

Virpax Pharmaceuticals's stock reverse split before market open on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virpax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS).

Company Calendar

• Today: 9/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRPX
• CIK: 1708331
• Web: www.virpaxpharma.com
• Phone: 610-727-4597
• Fax: N/A
• Employees: 7
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,554.34%
• Return on Assets: -338.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.65 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 1,242,000
• Free Float: 4,707,000
• Market Cap: $31.17 thousand
• Optionable: Not Optionable
• Beta: 1.49